Aptose Biosciences (NASDAQ:APTO) Earns Hold Rating from Analysts at StockNews.com

Equities researchers at StockNews.com began coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research report issued to clients and investors on Wednesday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price objective on shares of Aptose Biosciences in a research note on Friday, June 14th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, Aptose Biosciences presently has a consensus rating of “Moderate Buy” and an average target price of $9.00.

Aptose Biosciences Price Performance

Shares of Aptose Biosciences stock opened at $0.40 on Wednesday. The business has a 50-day simple moving average of $0.50 and a 200 day simple moving average of $0.95. Aptose Biosciences has a one year low of $0.33 and a one year high of $3.52. The firm has a market capitalization of $7.33 million, a price-to-earnings ratio of -0.07 and a beta of 1.25.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last released its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.43) EPS for the quarter, beating the consensus estimate of ($0.58) by $0.15. On average, sell-side analysts expect that Aptose Biosciences will post -2.62 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Aptose Biosciences stock. Armistice Capital LLC acquired a new stake in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm acquired 1,713,000 shares of the biotechnology company’s stock, valued at approximately $1,300,000. Armistice Capital LLC owned approximately 9.46% of Aptose Biosciences at the end of the most recent quarter. Hedge funds and other institutional investors own 26.62% of the company’s stock.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.